McCann Health has launched a new consultancy, Consulting at McCann Health, with two objectives. The first: consolidate its health consulting agencies. And the second? Ignite fresh thinking in pharma strategy.
The typically combative Carl Icahn is playing a different game with his latest biopharma investment. Announcing "a large position" in Allergan Tuesday, the activist investor heaped praise on CEO Brent Saunders.